Molecular epidemiology studies highlight HNSCC as a tumor type with a high prevalence of CCR8+ itTregs to evaluate the anti-tumor activity of an anti-CCR8 antibody. CHS-114 (SRF114) is currently being evaluated in a Phase 1 clinical trial (NCT05635643). Ethics Approval All animal studies ...
today announced the U.S. Food and Drug Administration’s (FDA) clearance of its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody,
Abstract 6008: Effective depletion of tumor-infiltrating Tregs by a novel anti-CCR8 antibody (LM-108): Addressing resistance associated with immune checkpoint inhibitors Immune checkpoint inhibitors (ICIs) have generated durable clinical responses in multiple tumor types, but their therapeutic efficacy is...
Briefly, samples were incubated overnight at 4°C on antibody-coated plates. Detection antibodies were allowed to incubate for 1 hr at room temperature, followed by addition of streptavidin-horseradish peroxidase for 30 min. Finally, TMB substrate solution was added and the reaction was stopped ...
Our preclinical studies have demonstrated that treatment of a PD-1 resistant mouse tumor model with an anti-CCR8 monoclonal antibody (mAb) depletes itTregs, reduces tumor growth, and enhances anti-PD-1 antitumor activity. CHS-114 an afucosylated mAb that binds CCR8, depletes itTregs, and ...
Patients received intravenous LM-108 at dose levels of 3 mg/kg Q2W, 6 mg/kg Q3W, or 10 mg/kg Q3W plus an anti-PD-1 antibody (intravenous pembrolizumab 200 mg Q3W or 400 mg Q6W or toripalimab 240 mg Q3W). The primary endpoint was investigator-assessed ORR per RECIST v1.1. The ...
ANTIBODY-dependent cell cytotoxicityT cellsIMMUNE checkpoint inhibitorsPHAGOCYTOSISRegulatory T cells (Tregs) are known to facilitate tumor progression by suppressing CD8 T cells within the tumor microenvironment (TME), thereby also hampering the effectiveness of immune checkpoint inhibitors (ICIs). While ...
Abstract 2866: BAY 3375968: An afucosylated anti-CCR8 antibody depleting activated intratumoral regulatory T cells as a cancer immunotherapydoi:10.1158/1538-7445.AM2022-2866Regulatory T cells (Tregs) play an indispensable role in mediating peripheral tolerance to self-antigens. They can also promote ...